AvandiaŽ - Key Messages
Potent antidiabetic PPAR? agonist
Effective in mono and combination therapy
Well characterized safety profile
- no signal of hepatotoxicity
- neutral effect on lipids
- minimal cardiovascular / hemodynamic effects
Positive Risk / Benefit Assessment